Source:http://linkedlifedata.com/resource/pubmed/id/10843770
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
6
|
pubmed:dateCreated |
2000-8-23
|
pubmed:abstractText |
In this study we assessed the usefulness of serum Transforming Growth Factor-beta1 (TGF-beta1) and soluble Fas (sFas) in distinguishing liver cirrhosis (LC) with and without hepatocellular carcinoma (HCC) as compared with alpha-fetoprotein (AFP). Serum TGF-beta1 and sFas levels were measured by ELISA in 51 LC patients, 54 patients with HCC and 30 healthy donors. Considering as a cut-off limit (mean+1SD of controls) 74 pg/ml and 637 pg/ml for TGF-beta1 and sFas, respectively, we computed serum concentrations of TGF-beta1 and sFas as a score (mean+/-SD). The positive frequency of serum TGF-beta1 levels in HCC patients (54%) was greater than in LC patients (26%) and healthy donors (3%). TGF-beta1 levels were higher in HCC (1.6+/-0.5) than in LC (1.1+/-0.2) (P<0.0001) and healthy donors (0.6+/-0.2). Using a cut-off limit of 82 pg/ml (mean+2SD), the positive frequency of TGF-beta1 was 20% in HCC patients. None of the controls and LC patients had TGF-beta1 levels higher than 82 pg/ml. The positive frequency of serum sFas levels was 100% in HCC patients, 98% in LC patients and 3% in healthy controls. Serum sFas levels were higher in HCC (2.5+/-0.7) than in LC (1.9+/-0.5) (P<0. 001) and healthy donors (0.6+/-0.3). No significant change of positive frequency was obtained by setting sFas cut-off at higher levels. sFas values did not correlate with TGF-beta1 levels. No relationship was found between TGF-beta1 amounts and AFP levels. However, in the 23% of HCC patients, with normal AFP values TGF-beta1 levels were higher than the cut off. These findings suggest the potential usefulness for TGF-beta1 assay in AFP-negative HCC.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
1043-4666
|
pubmed:author | |
pubmed:copyrightInfo |
Copyright 2000 Academic Press.
|
pubmed:issnType |
Print
|
pubmed:volume |
12
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
811-4
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:10843770-Adult,
pubmed-meshheading:10843770-Aged,
pubmed-meshheading:10843770-Antigens, CD95,
pubmed-meshheading:10843770-Carcinoma, Hepatocellular,
pubmed-meshheading:10843770-Female,
pubmed-meshheading:10843770-Humans,
pubmed-meshheading:10843770-Liver Cirrhosis,
pubmed-meshheading:10843770-Liver Neoplasms,
pubmed-meshheading:10843770-Male,
pubmed-meshheading:10843770-Middle Aged,
pubmed-meshheading:10843770-Regression Analysis,
pubmed-meshheading:10843770-Transforming Growth Factor beta,
pubmed-meshheading:10843770-Tumor Markers, Biological,
pubmed-meshheading:10843770-alpha-Fetoproteins
|
pubmed:year |
2000
|
pubmed:articleTitle |
Transforming growth factor beta1 and soluble Fas serum levels in hepatocellular carcinoma.
|
pubmed:affiliation |
Department of Internal Medicine, Immunology and Infectious Diseases, University of Bari Medical School, Policlinico, Bari, 70124, Italy. saccorodolfo@hotmail.com
|
pubmed:publicationType |
Journal Article,
Comparative Study
|